TY  - JOUR
TI  - Relationship Between PET/CT Response and  Survival in Patients with Non-Small-Cell  Lung Cancer Treated with Definitive  Chemoradiotherapy
AB  - We aimed to evaluate the relationship between PET/CT response and survival in patients with non-small cell lung cancer (NSCLC)  treated with curative chemoradiotherapy. Between January and December 2012, 51 patients were treated. The median age was 61  (29-79) and the M/F ratio was 46/5. Eighty two percent of the cases were stage III and 53% were squamous cell carcinoma. Median  6300 cGy (4860-7525) radiotherapy delivered and 92% of patients received chemotherapy. The median follow-up was 27 months  (7-96 months) in November 2019. The objective response was 71% with CT at 1 month and 76% with PET/CT at 3 months. There  was a significant correlation between response-1 and response-3 (p< 0.001). Tumor SUVmean3 < 2.81, SUVmax change ≥ 70% was  associated with response-1 (p< 0.05). The median and 5-year overall (OS) and progression-free (PFS) survival rates were 54 months,  40% and 35 months, 38%, respectively. In Cox model, for each 1 unit increase, SUVmeanbase (HR: 1.18, 95% CI: 1.01-1.38) and SU Vmean3 (HR: 2.65, 95% CI: 1.24-5.66) were found unfavorable factors for OS, whereas SUVmean3 (HR: 2.01, 95% CI: 1.02-3.93) was  also found to be a poor prognostic factor for PFS. PET/CT parameters can be used as useful markers for prognosis in patients with  NSCLC undergoing curative chemoradiotherapy. It is believed that early assessment during and after treatment can be advantageous  in terms of treatment modification.
AU  - Sarihan, Sureyya
AU  - Sigirli, Deniz
AU  - belge, gökçe
DO  - 10.4999/uhod.214343
PY  - 2021
JO  - Uluslararası Hematoloji-Onkoloji Dergisi
VL  - 31
IS  - 1
SN  - 1306-133X
SP  - 8
EP  - 18
DB  - TRDizin
UR  - http://search/yayin/detay/1178311
ER  -